Millipore Sigma Vibrant Logo

AB1510 Anti-Amyloid β Antibody, aa1-14 h β-amyloid

View Products on Sigmaaldrich.com
AB1510
100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Fulfillment and delivery delayed
Fulfillment and delivery delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWB, IHCRbSerumPolyclonal Antibody
      Description
      Catalogue NumberAB1510
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Amyloid β Antibody, aa1-14 h β-amyloid
      Alternate Names
      • Beta-APP
      • A-beta
      References
      Product Information
      FormatSerum
      PresentationRabbit serum with 0.01% thimerosal.
      Quality LevelMQ100
      Applications
      ApplicationAnti-Amyloid Antibody, β, aa1-14 h β-amyloid detects level of Amyloid & has been published & validated for use in WB, IH.
      Key Applications
      • Western Blotting
      • Immunohistochemistry
      Application NotesImmunohistochemistry on formic acid treated histological sections. Suggested working dilution is > 1:200. AB1510 will detect both cerebrovascular and core amyloid. Formic acid pretreatment (Vinters et al., 1988) involves deparaffinizing sections, follwed by incubation in a 99% formic acid solution (10-20 min), a tap water rinse (10 min), 0.3% H202 in tris-buffered saline, then 3.0% NGS (30 min) followed by primary antibody.

      Immunoblotting of formic acid extracts of brain tissue.

      ELISA, direct:>= 1:1000

      Optimal working dilutions must be determined by end user.
      Biological Information
      ImmunogenSynthetic peptide that corresponds to the first 14 amino acids of the N-terminal sequence of beta-amyloid. {DAEFRHDSGYEVHH}
      Epitopeaa1-14 h beta-amyloid
      HostRabbit
      SpecificityBeta amyloid. Sequence is contained in the Amyloid beta-A4 protein amino acids 672-685 of human APP. The sequence is identical in the following other related proteins:

      Cerebral vascular amyloid peptide) (CVAP) (Protease nexin-II) (PN-II) (APPI) (PreA4) [Contains: Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40); Gamma-CTF(59) (Gamma-secretase C-terminal fragment 59) (Amyloid intracellular domain 59) (AID(59)); Gamma-CTF(57) (Gamma-secretase C-terminal fragment 57).

      100% homology in human, pig, sheep, rabbit, bovine, 78% identities (11/14), with 12/14 positives (85%) in rat and mouse beta amyloid containing proteins.
      Species Reactivity
      • Human
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene.
      Gene Symbol
      • APP
      • ABPP
      • PN-II
      • AD1
      • A4
      • CVAP
      • PN2
      • ABETA
      • CTFgamma
      • APPI
      • PreA4
      • AAA
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P05067 # The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
      SIZE: 770 amino acids; 86943 Da
      SUBUNIT: Binds, via its C-terminus, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, MAPK8IP1, SHC1 and, Numb and Dab1 (By similarity). Binding to Dab1 inhibits its serine phosphorylation (By similarity). Also interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains) (By similarity), APPBP2 (via BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains (By similarity). Associates with microtubules in the presence of ATP and in a kinesin-dependent manner (By similarity). Interacts, through a C-terminal domain, with GNAO1. Amyloid beta-42 binds CHRNA7 in hippocampal neurons. Beta-amyloid associates with HADH2. Soluble APP binds, via its N-terminal head, to FBLN1. Interacts with CPEB1 (By similarity).
      SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. Note=Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O- glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C- terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with Fe65. Beta- APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment.
      TISSUE SPECIFICITY: Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex- opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra- striate and motor cortices. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes.
      DOMAIN: SwissProt: P05067 The basolateral sorting signal (BaSS) is required for sorting of membrane proteins to the basolateral surface of epithelial cells. & The NPXY sequence motif found in many tyrosine- phosphorylated proteins is required for the specific binding of the PID domain. However, additional amino acids either N- or C- terminal to the NPXY motif are often required for complete interaction. The PID domain-containing proteins which bind APP require the YENPTY motif for full interaction. These interactions are independent of phosphorylation on the terminal tyrosine residue. The NPXY site is also involved in clathrin-mediated endocytosis.
      PTM: Proteolytically processed under normal cellular conditions. Cleavage by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). & Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides. & N- and O-glycosylated. O-linkage of chondroitin sulfate to the L-APP isoforms produces the APP proteoglycan core proteins, the appicans. The chondroitin sulfate chain of appicans contains 4-O-sulfated galactose in the linkage region and chondroitin sulfate E in the repeated disaccharide region (By similarity). & Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell- cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin. & Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides.
      DISEASE: SwissProt: P05067 # Defects in APP are a cause of autosomal dominant Alzheimer disease (AD) [MIM:104300]. AD is the most prevelant form of dementia, characterized by neurofibrillary tangles and amyloid plaques deposition in the brain. Identical lesions occur in the neurons of aged Down syndrome but at an earlier age than in AD. The major constituent of these neuritic plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. Mutations occurring at the beta-amyloid N-terminal, such as the Swedish double mutation, appear to increase levels of beta-amyloid by facilitating beta-secretase cleavage resulting in elevated levels of both beta-APP42 and beta-APP40. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31, are also implicated in AD neuronal death. Alzheimer disease caused by mutations in APP is a rare occurrence and usually causes the familial or early-onset form of the disease (FAD). Flemish-type AD is characterized by, in addition to presenile dementia, cerebral hemorrhaging due to cerebral amyloid angiopathy which is similar to, but distinct from, cerebroarterial amyloidosis Dutch type. Only about 5% of all cases of Alzheimer disease are caused by FAD mutations, the rest are sporadic. & Defects in APP are the cause of hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWAD) [MIM:609065]. HCHWAD is characterized by amyloid deposits in cerebral vessels. The principal clinical characteristics are recurring cerebral hemorrhages, sometimes preceded by migrainous headaches or mental cleavage. Beta-APP40 is the predominant form of cerebrovascular amyloid. & Defects in APP are the cause of hereditary cerebroarterial amyloidosis Iowa type [MIM:605714]. Hereditary cerebroarterial amyloidosis Iowa type is an autosomal dominant dementia beginning in the sixth or seventh decade of life. The patients have progressive aphasic dementia, leukoencephalopathy, and occipital calcifications. They do not present cerebral hemorrhaging.
      SIMILARITY: Belongs to the APP family. & Contains 1 BPTI/Kunitz inhibitor domain.
      MISCELLANEOUS: Chelation of metal ions, notably copper, iron and zinc, can induce histidine-bridging between beta-amyloid molecules resulting in beta-amyloid-metal aggregates. The affinity for copper is much higher than for other transient metals and is increased under acidic conditions. Extracellular zinc-binding increases binding of heparin to APP and inhibits collagen-binding.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain at -20°C in undiluted aliquots for up to 12 months after date of receipt. Avoid repeated freeze/thaw cycles.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      AB1510 04053252677441

      Documentation

      Anti-Amyloid β Antibody, aa1-14 h β-amyloid SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-Amyloid β Antibody, aa1-14 h β-amyloid Certificates of Analysis

      TitleLot Number
      RABBIT ANTI-HUMAN BETA AMYLOID POLYCLONAL ANTIBODY - 2137983 2137983
      RABBIT ANTI-HUMAN BETA AMYLOID - 3862539 3862539
      RABBIT ANTI-HUMAN BETA AMYLOID - 4058980 4058980
      RABBIT ANTI-HUMAN BETA AMYLOID -2628285 2628285
      RABBIT ANTI-HUMAN BETA AMYLOID -2831783 2831783
      RABBIT ANTI-HUMAN BETA AMYLOID -2861010 2861010
      RABBIT ANTI-HUMAN BETA AMYLOID POLYCLONAL ANTIBODY 3006326
      RABBIT ANTI-HUMAN BETA AMYLOID POLYCLONAL ANTIBODY - 3543878 3543878

      References

      Reference overviewApplicationPub Med ID
      Optineurin immunoreactivity in neuronal and glial intranuclear inclusions in adult-onset neuronal intranuclear inclusion disease.
      Nakamura, M; Murray, ME; Lin, WL; Kusaka, H; Dickson, DW
      American journal of neurodegenerative disease  3  93-102  2014

      Show Abstract
      Immunofluorescence25232514 25232514
      Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis.
      Melnikova, T; Fromholt, S; Kim, H; Lee, D; Xu, G; Price, A; Moore, BD; Golde, TE; Felsenstein, KM; Savonenko, A; Borchelt, DR
      The Journal of neuroscience : the official journal of the Society for Neuroscience  33  3765-79  2013

      Show Abstract
      23447589 23447589
      Retromer disruption promotes amyloidogenic APP processing.
      Sullivan, CP; Jay, AG; Stack, EC; Pakaluk, M; Wadlinger, E; Fine, RE; Wells, JM; Morin, PJ
      Neurobiology of disease  43  338-45  2011

      Show Abstract
      21515373 21515373
      Amphetamine effects on brain protein structure and oxidative stress as revealed by FTIR microspectroscopy.
      A Rodríguez-Casado, I Alvarez, A Toledano, E de Miguel, P Carmona
      Biopolymers  86  437-46  2007

      Show Abstract
      17480001 17480001
      Clinicopathological study of two subtypes of Pick's disease in Japan.
      Odawara, Toshinari, et al.
      Dement Geriatr Cogn Disord, 15: 19-25 (2003)  2003

      12457075 12457075
      Antibodies raised against different portions of A4 protein identify a subset of plaques in Down's syndrome.
      Spargo, E, et al.
      Neurosci. Lett., 115: 345-50 (1990)  1990

      2146532 2146532
      CNS amyloid proteins in neurodegenerative diseases.
      Roberts, G W, et al.
      Neurology, 38: 1534-40 (1988)  1988

      2901696 2901696
      Immunohistochemical study of Alzheimer's disease using antibodies to synthetic amyloid and fibronectin.
      Koike, F, et al.
      J. Neurol. Sci., 85: 9-15 (1988)  1988

      2968440 2968440
      Immunohistochemical study of cerebral amyloid angiopathy. II. Enhancement of immunostaining using formic acid pretreatment of tissue sections
      Vinters, H. V. et al.
      Am. J. Pathol., 133(1):150-162 (1988)  1988

      3177597 3177597
      Human amyloidosis, Alzheimer disease and related disorders.
      Castaño, E M and Frangione, B
      Lab. Invest., 58: 122-32 (1988)  1988

      3276958 3276958

      Newsletters / Publications

      Title
      Research Focus - Volume 2, 2013